MENTAX Drug Patent Profile

Which patents cover Mentax, and when can generic versions of Mentax launch?

Mentax is a drug marketed by Norvium Bioscience and is included in two NDAs.

The generic ingredient in MENTAX is butenafine hydrochloride. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mentax

A generic version of MENTAX was approved as butenafine hydrochloride by TARO on November 16^th, 2017.

Summary for MENTAX

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	104
Patent Applications:	339
Drug Prices:	Drug price information for MENTAX
What excipients (inactive ingredients) are in MENTAX?	MENTAX excipients list
DailyMed Link:	MENTAX at DailyMed

See drug prices for MENTAX

US Patents and Regulatory Information for MENTAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norvium Bioscience	MENTAX	butenafine hydrochloride	CREAM;TOPICAL	020524-001	Oct 18, 1996		DISCN	Yes	No
Norvium Bioscience	MENTAX-TC	butenafine hydrochloride	CREAM;TOPICAL	021408-001	Oct 17, 2002		DISCN	No	No

Expired US Patents for MENTAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Norvium Bioscience	MENTAX	butenafine hydrochloride	CREAM;TOPICAL	020524-001	Oct 18, 1996

International Patents for MENTAX

See the table below for patents covering MENTAX around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H02209848	NAPHTHYLMETHYLAMINE DERIVATIVE AND ANTIFUNGAL AGENT CONTAINING THE SAME DERIVATIVE AS ACTIVE INGREDIENT
Hong Kong	111793	AMINE DERIVATIVES,PROCESSES FOR PREPARING THE SAME AND FUNGICIDES CONTAINING THE SAME
China	85104330
Singapore	69893
Japan	S6145	NAPHTHYLMETHYLAMINE DERIVATIVE AND ANTIFUNGAL CONTAINING THE SAME
Germany	10399014

Supplementary Protection Certificates for MENTAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0164697	91031	Luxembourg		91031, EXPIRES: 20100606

MENTAX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for MENTAX

Introduction

MENTAX, a brand name for the antifungal drug butenafine hydrochloride, has been a part of the pharmaceutical market since its FDA approval in 1996. Here, we will delve into the market dynamics and financial trajectory of MENTAX, exploring its current status, market trends, and financial implications.

Approval and Formulations

MENTAX was approved by the FDA on October 18, 1996, in the formulation of a 1% cream for topical use. It is manufactured by Norvium Bioscience and is indicated for the treatment of tinea (pityriasis) versicolor due to Malassezia furfur[1][4].

Market Status

All formulations of MENTAX have been discontinued, which significantly impacts its market presence and financial performance. The discontinuation means that the drug is no longer being produced or sold under the MENTAX brand name[1].

Generic and Alternative Options

Despite the discontinuation of MENTAX, butenafine hydrochloride remains available in the market through other brand names and generic versions. For example, it is also marketed under the trade names Butop in India and is the active ingredient in Lotrimin Ultra. This availability ensures that patients still have access to the antifungal treatment, albeit under different brand names[4].

Safety and Authenticity Concerns

The discontinuation of MENTAX has also raised concerns about fraudulent online pharmacies selling counterfeit versions of the drug. It is crucial for consumers to purchase medications from reputable sources to avoid potential health risks[1].

Antifungal Market Trends

The antifungal market, while not specifically focused on MENTAX due to its discontinuation, continues to grow driven by increasing fungal infections and the need for effective treatments. Butenafine hydrochloride, the active ingredient in MENTAX, remains a viable option due to its superior fungicidal activity against dermatophytes and other fungi[4].

Financial Implications

Given that MENTAX is no longer in production, the financial trajectory for this specific brand is essentially non-existent. The revenue and profitability associated with MENTAX have ceased, and any financial reports would reflect this discontinuation.

Impact on Manufacturer

The discontinuation of MENTAX would likely have a minimal impact on the overall financial performance of Norvium Bioscience if they have diversified their product portfolio. However, it could result in a loss of market share in the antifungal segment, which might be mitigated by other products or new market entries.

Consumer Impact

For consumers, the discontinuation of MENTAX means they must seek alternative treatments for fungal infections. While butenafine hydrochloride is still available under other brand names, the change may require adjustments in prescription or over-the-counter purchases.

Competitive Landscape

The competitive landscape in the antifungal market remains dynamic, with various drugs and treatments available. Butenafine hydrochloride's effectiveness, particularly against dermatophytes, keeps it a competitive option despite the discontinuation of the MENTAX brand[4].

Regulatory Considerations

Regulatory bodies continue to monitor the safety and efficacy of antifungal drugs, including butenafine hydrochloride. Ensuring compliance with FDA regulations is crucial for any manufacturer producing this or similar drugs.

Conclusion

The discontinuation of MENTAX marks the end of its market presence and financial trajectory. However, the active ingredient butenafine hydrochloride remains a significant player in the antifungal market, available through other brand names and formulations.

Key Takeaways

• MENTAX has been discontinued, ending its market presence and financial performance.
• Butenafine hydrochloride, the active ingredient, is still available under other brand names.
• The antifungal market continues to grow, driven by increasing fungal infections.
• Consumers must seek alternative treatments for fungal infections.
• Regulatory compliance remains crucial for manufacturers of antifungal drugs.

FAQs

What is MENTAX used for?

MENTAX is used for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur[1][4].

Why was MENTAX discontinued?

All formulations of MENTAX have been discontinued, though the exact reasons are not specified in available sources[1].

Is butenafine hydrochloride still available?

Yes, butenafine hydrochloride is still available under other brand names such as Butop and Lotrimin Ultra[4].

What are the safety concerns with buying MENTAX online?

There is a risk of fraudulent online pharmacies selling counterfeit versions of MENTAX, which can be unsafe. It is advised to purchase medications from reputable sources[1].

How does the discontinuation of MENTAX affect the antifungal market?

The discontinuation of MENTAX does not significantly impact the overall antifungal market, as butenafine hydrochloride remains available through other brands and formulations[4].

Sources

1. Generic Mentax Availability - Drugs.com
2. Methanex (TSX:MX) - Stock Price, News & Analysis - Simply Wall St
3. Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion ... - PR Newswire
4. BUTENAFINE - Inxight Drugs
5. Methanex Reports Higher Fourth Quarter 2023 Earnings as ... - Methanex.com